|
US6248334B1
(en)
|
1997-01-08 |
2001-06-19 |
Henry M. Jackson Foundation For The Advancement Of Military Medicine |
Process for preparing conjugate vaccines including free protein and the conjugate vaccines, immunogens, and immunogenic reagents produced by this process
|
|
US6299881B1
(en)
|
1997-03-24 |
2001-10-09 |
Henry M. Jackson Foundation For The Advancement Of Military Medicine |
Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
|
|
EP0977588B1
(de)
*
|
1997-04-24 |
2004-10-06 |
Henry M. Jackson Foundation For The Advancement Of Military Medicine |
Kopplung unmodifizierter proteinen an haloacyl- oder dihaloacyl-derivatisierten polysacchariden zur herstellung von protein-polysaccharide impfstoffen
|
|
AU763349B2
(en)
*
|
1998-02-05 |
2003-07-17 |
Henry M. Jackson Foundation For The Advancement Of Military Medicine |
Simplified method for removing free protein during preparation of protein-polysaccharide conjugates and vaccines using restricted-access media
|
|
CA2331258C
(en)
*
|
1998-06-12 |
2011-09-20 |
Henry M. Jackson Foundation For The Advancement Of Military Medicine |
Enhancement of b cell activation and immunoglobulin secretion by co-stimulation of receptors for antigen and ebv gp350/220
|
|
WO2001040277A2
(en)
*
|
1999-12-06 |
2001-06-07 |
Eukarion, Inc. |
Carbohydrate-aminated glycoproteins
|
|
US8048432B2
(en)
|
2003-08-06 |
2011-11-01 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Polysaccharide-protein conjugate vaccines
|
|
AU2004281630A1
(en)
*
|
2003-08-06 |
2005-04-28 |
Bio-Manguinhos/Fiocruz |
Process for preparing polysaccharide-protein conjugate vaccines
|
|
GB0323103D0
(en)
|
2003-10-02 |
2003-11-05 |
Chiron Srl |
De-acetylated saccharides
|
|
US9486515B2
(en)
|
2005-06-27 |
2016-11-08 |
Glaxosmithkline Biologicals S.A. |
Immunogenic composition
|
|
CN103251940A
(zh)
|
2005-12-22 |
2013-08-21 |
葛兰素史密丝克莱恩生物有限公司 |
疫苗
|
|
GB0607088D0
(en)
|
2006-04-07 |
2006-05-17 |
Glaxosmithkline Biolog Sa |
Vaccine
|
|
EP2491947A3
(de)
|
2006-09-07 |
2012-10-17 |
GlaxoSmithKline Biologicals S.A. |
Impfstoff
|
|
GB0700136D0
(en)
|
2007-01-04 |
2007-02-14 |
Glaxosmithkline Biolog Sa |
Process for manufacturing vaccines
|
|
WO2008135514A1
(en)
|
2007-05-02 |
2008-11-13 |
Glaxosmithkline Biologicals S.A. |
Vaccine
|
|
MX2009013949A
(es)
|
2007-06-26 |
2010-05-24 |
Glaxosmithkline Biolog Sa |
Vacuna que comprende conjugados de polisacárido capsular de streptococcus pneumoniae.
|
|
WO2010141312A2
(en)
|
2009-06-01 |
2010-12-09 |
Wake Forest University Health Sciences |
Flagellin fusion proteins and conjugates comprising pneumococcus antigens and methods of using the same
|
|
WO2011036560A2
(en)
|
2009-09-23 |
2011-03-31 |
Novartis Ag |
Glycoconjugate compositions and methods for treatment of hiv
|
|
GB0917647D0
(en)
|
2009-10-08 |
2009-11-25 |
Glaxosmithkline Biolog Sa |
Expression system
|
|
US9044517B2
(en)
*
|
2009-12-17 |
2015-06-02 |
Fina Biosolutions, Llc |
Activation of polysaccharides via the cyanylating agent, 1-cyano-4-pyrrolidinopyridinium tetrafluoroborate (CPPT), in the preparation of polysaccharide/protein conjugate vaccines
|
|
GB201003924D0
(en)
|
2010-03-09 |
2010-04-21 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
|
GB201003922D0
(en)
|
2010-03-09 |
2010-04-21 |
Glaxosmithkline Biolog Sa |
Conjugation process
|
|
GB201106225D0
(en)
|
2011-04-13 |
2011-05-25 |
Glaxosmithkline Biolog Sa |
Fermentation process
|
|
AU2012253359B2
(en)
*
|
2011-05-11 |
2017-06-08 |
Children's Medical Center Corporation |
Multiple antigen presenting immunogenic composition, and methods and uses thereof
|
|
SA115360586B1
(ar)
|
2012-03-09 |
2017-04-12 |
فايزر انك |
تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
|
|
JP2016501550A
(ja)
|
2012-12-27 |
2016-01-21 |
グリコヴァキシン アーゲー |
Crm197に関する方法及び組成物
|
|
CA2900008C
(en)
|
2013-02-07 |
2025-10-07 |
Children's Medical Center Corporation |
PROTEIN ANTIGENS THAT CONFER PROTECTION AGAINST COLONIZATION AND/OR PNEUMOCOCCAL DISEASE
|
|
CN103113836B
(zh)
*
|
2013-03-09 |
2015-08-12 |
谭志刚 |
一种白乳胶添加剂及其制备方法
|
|
EP4098276A1
(de)
|
2013-09-08 |
2022-12-07 |
Pfizer Inc. |
Neisseria meningitidis-zusammensetzungen und verfahren dafür
|
|
US11708411B2
(en)
|
2013-12-20 |
2023-07-25 |
Wake Forest University Health Sciences |
Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
|
|
MX371453B
(es)
|
2014-01-21 |
2020-01-29 |
Pfizer |
Polisacaridos capsulares de streptococcus pneumoniae y conjugados de los mismos.
|
|
US11160855B2
(en)
|
2014-01-21 |
2021-11-02 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
|
CA3206112A1
(en)
|
2014-01-21 |
2015-07-30 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
|
PL3244917T3
(pl)
|
2015-01-15 |
2023-07-17 |
Pfizer Inc. |
Kompozycje immunogenne do zastosowania w szczepionkach przeciwko pneumokokom
|
|
IL255106B2
(en)
|
2015-05-04 |
2023-04-01 |
Pfizer |
Protein-polysaccharide conjugates of group b streptococcus, methods for preparing conjugates, immunogenic preparations containing conjugates and their uses
|
|
ES2857474T3
(es)
|
2015-06-23 |
2021-09-29 |
Biological E Ltd |
Vacuna conjugada neumocócica multivalente
|
|
EP3325008B1
(de)
|
2015-07-21 |
2025-09-10 |
Pfizer Inc. |
Immunogene zusammensetzungen mit konjugierten kapselsaccharid-antigenen, kits damit und verwendungen davon
|
|
GB201518684D0
(en)
|
2015-10-21 |
2015-12-02 |
Glaxosmithkline Biolog Sa |
Vaccine
|
|
WO2017085586A1
(en)
|
2015-11-20 |
2017-05-26 |
Pfizer Inc. |
Immunogenic compositions for use in pneumococcal vaccines
|
|
GB201610599D0
(en)
|
2016-06-17 |
2016-08-03 |
Glaxosmithkline Biologicals Sa |
Immunogenic Composition
|
|
EP3269385A1
(de)
|
2016-07-12 |
2018-01-17 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Pneumokokken-polysaccharid-proteinkonjugatzusammensetzung
|
|
WO2017220753A1
(en)
|
2016-06-22 |
2017-12-28 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Pneumococcal polysaccharide-protein conjugate composition
|
|
MY199342A
(en)
|
2016-08-05 |
2023-10-24 |
Sanofi Pasteur Inc |
Multivalent pneumococcal polysaccharide-protein conjugate composition
|
|
KR102437120B1
(ko)
|
2016-08-05 |
2022-08-25 |
사노피 파스퇴르 인코포레이티드 |
다가 폐렴구균 다당류-단백질 접합체 조성물
|
|
AU2017321863B2
(en)
|
2016-09-02 |
2024-07-11 |
Sanofi Vaccines US Inc. |
Neisseria meningitidis vaccine
|
|
JP2019529497A
(ja)
|
2016-09-30 |
2019-10-17 |
バイオロジカル イー リミテッド |
多糖類−タンパク質コンジュゲートを含む多価肺炎球菌ワクチン組成物
|
|
US10751402B2
(en)
|
2016-11-09 |
2020-08-25 |
Pfizer Inc. |
Immunogenic compositions and uses thereof
|
|
US11413344B2
(en)
|
2017-01-20 |
2022-08-16 |
Pfizer Inc. |
Immunogenic compositions for use in pneumococcal vaccines
|
|
PE20191107A1
(es)
|
2017-01-31 |
2019-08-26 |
Pfizer |
Composiciones de neisseria meningitidis y metodos respectivos
|
|
CN110225757A
(zh)
|
2017-01-31 |
2019-09-10 |
默沙东公司 |
由肺炎链球菌血清型19f生产荚膜多糖蛋白缀合物的方法
|
|
US20200054740A1
(en)
|
2017-02-24 |
2020-02-20 |
Merck Sharp & Dohme Corp. |
Pneumococcal conjugate vaccine formulations
|
|
EP3600400A4
(de)
|
2017-03-28 |
2021-01-13 |
The Children's Medical Center Corporation |
Auf system mit mehreren antigenen (maps) basierter staphylococcus-aureus-impfstoff, immunogene zusammensetzung und verwendungen davon
|
|
CN111065417B
(zh)
|
2017-06-23 |
2024-04-19 |
美商艾芬尼维克斯公司 |
免疫原性组合物
|
|
PL3678654T3
(pl)
|
2017-09-07 |
2024-12-16 |
Merck Sharp & Dohme Llc |
Polisacharydy pneumokokowe i ich zastosowanie w immunogennych koniugatach polisacharyd-białko nośnikowe
|
|
US20210177957A1
(en)
|
2017-12-06 |
2021-06-17 |
Merck Sharp & Dohme Corp. |
Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
|
|
GB201721582D0
(en)
|
2017-12-21 |
2018-02-07 |
Glaxosmithkline Biologicals Sa |
S aureus antigens and immunogenic compositions
|
|
GB201721576D0
(en)
|
2017-12-21 |
2018-02-07 |
Glaxosmithkline Biologicals Sa |
Hla antigens and glycoconjugates thereof
|
|
CA3106291A1
(en)
|
2018-07-19 |
2020-01-23 |
Glaxosmithkline Biologicals Sa |
Processes for preparing dried polysaccharides
|
|
TW202019470A
(zh)
|
2018-09-12 |
2020-06-01 |
美商艾芬尼維克斯公司 |
多價肺炎球菌疫苗
|
|
KR102922338B1
(ko)
|
2018-09-12 |
2026-02-05 |
더 칠드런스 메디칼 센터 코포레이션 |
폐렴구균 융합 단백질 백신
|
|
BR112021005425A2
(pt)
|
2018-09-23 |
2021-06-15 |
Biological E Limited |
polissacarídeos capsulares purificados de streptococcus pneumoniae
|
|
SG11202106179VA
(en)
|
2018-10-12 |
2021-07-29 |
Biological E Ltd |
Multivalent pneumococcal polysaccharide-protein conjugate vaccine
|
|
CA3120922A1
(en)
|
2018-12-12 |
2020-06-18 |
Pfizer Inc. |
Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
|
|
EP3894431A2
(de)
|
2018-12-12 |
2021-10-20 |
GlaxoSmithKline Biologicals SA |
Modifizierte trägerproteine zur o-verknüpften glykosylierung
|
|
KR20240169145A
(ko)
|
2018-12-19 |
2024-12-02 |
머크 샤프 앤드 돔 엘엘씨 |
스트렙토코쿠스 뉴모니아에 폴리사카라이드-단백질 접합체를 포함하는 조성물 및 그의 사용 방법
|
|
EP3923982A1
(de)
|
2019-02-11 |
2021-12-22 |
Pfizer Inc. |
Neisseria meningitidis-zusammensetzungen und verfahren dafür
|
|
JP7239509B6
(ja)
|
2019-02-22 |
2023-03-28 |
ファイザー・インク |
細菌多糖類を精製するための方法
|
|
US20220184199A1
(en)
|
2019-04-10 |
2022-06-16 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
|
|
EP3757217A1
(de)
|
2019-06-27 |
2020-12-30 |
GlaxoSmithKline Biologicals S.A. |
Verfahren zur proteinaufreinigung
|
|
MX2022001241A
(es)
|
2019-07-31 |
2022-04-20 |
Sanofi Pasteur Inc |
Composiciones de conjugados neumococicos multivalentes polisacarido - proteina y metodos para usar los mismos.
|
|
EP3777884A1
(de)
|
2019-08-15 |
2021-02-17 |
GlaxoSmithKline Biologicals S.A. |
Immunogene zusammensetzung
|
|
WO2021059181A1
(en)
|
2019-09-27 |
2021-04-01 |
Pfizer Inc. |
Neisseria meningitidis compositions and methods thereof
|
|
WO2021099982A1
(en)
|
2019-11-22 |
2021-05-27 |
Glaxosmithkline Biologicals Sa |
Dosage and administration of a bacterial saccharide glycoconjugate vaccine
|
|
CN115362177A
(zh)
|
2020-02-21 |
2022-11-18 |
辉瑞公司 |
糖类的纯化
|
|
EP3900739A1
(de)
|
2020-04-21 |
2021-10-27 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Synthetische streptococcus-pneumoniae-saccharid-konjugate zum konservierten membranprotein
|
|
EP3919076A1
(de)
|
2020-06-02 |
2021-12-08 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Synthetische oligosaccharidimpfstoffe gegen streptococcus pneumoniae mit mikropartikel-adjuvans-formulierungen
|
|
JP2023529925A
(ja)
|
2020-06-12 |
2023-07-12 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
ナノ粒子ワクチンを使用する細菌免疫化
|
|
CN115996749A
(zh)
|
2020-06-25 |
2023-04-21 |
葛兰素史克生物有限公司 |
经修饰的外毒素a蛋白
|
|
EP4203995A1
(de)
|
2020-08-26 |
2023-07-05 |
Pfizer Inc. |
Gruppe-b-streptococcus-polysaccharid-protein-konjugate, verfahren zur herstellung von konjugaten, immunogene zusammensetzungen mit konjugaten und verwendungen davon
|
|
PH12023550020A1
(en)
|
2020-09-17 |
2024-03-11 |
Janssen Pharmaceuticals Inc |
Multivalent vaccine compositions and uses thereof
|
|
EP4232593A1
(de)
|
2020-10-22 |
2023-08-30 |
Pfizer Inc. |
Verfahren zur reinigung von bakteriellen polysacchariden
|
|
AU2021373358B2
(en)
|
2020-11-04 |
2026-01-08 |
Pfizer Inc. |
Immunogenic compositions for use in pneumococcal vaccines
|
|
WO2023039223A1
(en)
|
2021-09-09 |
2023-03-16 |
Affinivax, Inc. |
Multivalent pneumococcal vaccines
|
|
WO2023111826A1
(en)
|
2021-12-14 |
2023-06-22 |
Glaxosmithkline Biologicals Sa |
Bacterial immunization using qbeta hairpin nanoparticle constructs
|
|
WO2023118033A1
(en)
|
2021-12-22 |
2023-06-29 |
Glaxosmithkline Biologicals Sa |
Vaccine
|
|
GB202302579D0
(en)
|
2023-02-23 |
2023-04-12 |
Glaxosmithkline Biologicals Sa |
Immunogenic composition
|
|
WO2025032535A2
(en)
|
2023-08-09 |
2025-02-13 |
Glaxosmithkline Biologicals Sa |
Modified proteins
|
|
WO2025032534A2
(en)
|
2023-08-09 |
2025-02-13 |
Glaxosmithkline Biologicals Sa |
Modified proteins
|
|
WO2025172892A1
(en)
|
2024-02-16 |
2025-08-21 |
Glaxosmithkline Biologicals Sa |
Modified proteins and methods
|
|
WO2026038177A1
(en)
|
2024-08-16 |
2026-02-19 |
Pfizer Inc. |
Immunogenic compositions and uses thereof
|